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Buruli Ulcer (BU), caused by Mycobacterium ulcerans, is an emerging necrotizing skin 
disease.Currently, antibiotherapy with rifampicin and streptomycin is recommended by the 
WHO, but in extensive ulcerative lesions,surgical resection of the infected skin is still 
necessary. Bacteriophages and their lysins (Lys) are a class of antimicrobial agents that 
have been regarded as an alternative method tocontrol bacterial infections. The overall 
goal of this study is to evaluate the efficacy of mycophages and Lys in the control of M. 
ulcerans, as a novel therapeutic approach against BU. 
After establishing the antimycobacterial activity of mycobacteriophage D29 in vitro, 
we further tested its efficacy in vivo. For that mice were injected s.c. with a single dose of 
mycophage D29 in infected footpads, at an advanced stage of infection. The efficacy of 
phage treatment was evaluated by footpad swellingand viable M. ulcerans growth. We 
show that a single injection of mycophageD29 can effectively decrease M. ulcerans 
proliferation and prevent footpad ulceration. 
Additionally, we wanted to determine whether mycophage Lys were effective in 
controlling M. ulcerans proliferation. For that, Lys were expressed in an E. coli 
BL21(DE3)(pET) systemand purified by an affinity chromatography. In order to evaluate 
the antimicrobial activity of Lys, a lysoplate assay was performed with M. ulcerans isolates 
from endemic BU areas. Our results show that Lys has lytic activity in vitro against M. 
ulcerans isolates,in a dose dependent manner as demonstrated by induced spots in 
bacterial lawns. 
Our next step was to evaluate the bioavaibility and cytotoxicity of Lys in vivo. At 
different time points after s.c. Lys injection in the footpad, the presence of protein in 
tissue supernant and in the serum of mice was detected by western blotting. Histological 
analysis was performed on footpad tissue sections stained with hematoxylin and eosin. 
We observed no significant alterations in the footpad of treated mice, showing that Lys is 
not cytotoxic in vivo. Importantly, our results show an enzimatic activity associated with 
the detection of Lys in footpads of mice, at least 6h after s.c. injection. 
After these promising results our research is now focused on therapeutic studies to 
test Lys activity in vivo against M. ulcerans. One possible approach to improve Lys 
bioavailability could be the association of Lys with a drug delivery system with topical 
application. 
 
 
  
